Psychiatric advance directives for people living with schizophrenia, bipolar I disorders, or schizoaffective disorders: Study protocol for a randomized controlled trial – DAiP study

Aurelie Tinland (1) , Léa Leclerc (2) , Sandrine Loubiere (1) , Frédéric Mougeot (3) , Tim Greacen (4) , Magali Pontier , Nicolas Franck (5) , Christophe Lançon (6) , Mohamed Boucekine (1) , Pascal Auquier (1)

1 CEReSS - Centre d'études et de recherche sur les services de santé et la qualité de vie
2 AMU MED - Aix-Marseille Université - Faculté de médecine
3 CMW - Centre Max Weber
4 Laboratoire de Recherche
5 ISC - Institut des Sciences Cognitives
6 Pôle de psychiatrie

Background: Compulsory admission to psychiatric hospital is rising despite serious ethical concerns. Among measures to reduce compulsory admissions, Psychiatric Advance Directives (PAD) are the most promising, with intensive PAD (i.e. facilitated and shared) being the most effective. The aim of the study is to experiment Psychiatric Advance Directives in France.

Domains: Life Sciences [q-bio]; Santé publique et épidémiologie

Aurelie Tinland, Léa Leclerc, Sandrine Loubiere, Frédéric Mougeot, Tim Greacen, et al.. Psychiatric advance directives for people living with schizophrenia, bipolar I disorders, or schizoaffective disorders: Study protocol for a randomized controlled trial – DAiP study. BMC Psychiatry, 2019, 19 (1), ⟨10.1186/s12888-019-2416-9⟩. ⟨hal-02473095⟩